PWM
KALV

Parkworth Wealth Management’s KalVista Pharmaceuticals KALV Stock Holding History

Parkworth Wealth Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$249 Buy
+22
New +$269 ﹤0.01% 877

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Parkworth Wealth Management's KALV Position: Q2 2025 in Review

Parkworth Wealth Management opened a new position in KalVista Pharmaceuticals (KALV) in Q2 2025: 22 shares worth $249. The stake represents ﹤0.01% of the portfolio and ranks #877 among its holdings.

139 funds tracked by Wall St. Rank hold KALV as of Q2 2025.

  • Parkworth Wealth Management held 22 shares of KalVista Pharmaceuticals worth $249 as of Q2 2025.
  • KalVista Pharmaceuticals was a new Parkworth Wealth Management position in Q2 2025.
  • KalVista Pharmaceuticals made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #877 holding.
  • 139 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.